 Connection
David Ivy to Epoprostenol
This is a "connection" page, showing publications David Ivy has written about Epoprostenol.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.336 |
|
|
|
-
Takatsuki S, Parker DK, Doran AK, Friesen RH, Ivy DD. Acute pulmonary vasodilator testing with inhaled treprostinil in children with pulmonary arterial hypertension. Pediatr Cardiol. 2013 Apr; 34(4):1006-12.
Score: 0.374
-
Ivy DD, Calderbank M, Wagner BD, Dolan S, Nyquist AC, Wade M, Nickels WM, Doran AK. Closed-hub systems with protected connections and the reduction of risk of catheter-related bloodstream infection in pediatric patients receiving intravenous prostanoid therapy for pulmonary hypertension. Infect Control Hosp Epidemiol. 2009 Sep; 30(9):823-9.
Score: 0.298
-
Ivy DD, Claussen L, Doran A. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil. Am J Cardiol. 2007 Mar 01; 99(5):696-8.
Score: 0.249
-
Ivy DD, Doran A, Claussen L, Bingaman D, Yetman A. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan. Am J Cardiol. 2004 Apr 01; 93(7):943-6.
Score: 0.205
-
Hopper RK, Ivy DD, Yung D, Mullen MP, Hanna BD, Kirkpatrick E, Hirsch R, Austin ED, Fineman J, Solum D, Deng CQ, Feinstein JA. Pharmacokinetics of Oral Treprostinil in Children With Pulmonary Arterial Hypertension. J Cardiovasc Pharmacol. 2020 07; 76(1):94-100.
Score: 0.158
-
Hall K, Ogawa M, Sakarovitch C, Hopper RK, Adamson GT, Hanna B, Ivy DD, Miller-Reed K, Yung D, McCarthy E, Siehr-Handler SL, Feinstein JA. Subcutaneous and Intravenous Treprostinil Pharmacokinetics in Children With Pulmonary Vascular Disease. J Cardiovasc Pharmacol. 2019 06; 73(6):383-393.
Score: 0.147
-
Parker DK, Shen S, Zheng J, Ivy DD, Crotwell DN, Hotz JC, DiBlasi RM. Inhaled Treprostinil Drug Delivery During Mechanical Ventilation and Spontaneous Breathing Using Two Different Nebulizers. Pediatr Crit Care Med. 2017 Jun; 18(6):e253-e260.
Score: 0.128
-
Ivy DD, Wiggins JW, Badesch DB, Kinsella JP, Kelminson LL, Abman SH. Nitric oxide and prostacyclin treatment of an infant with primary pulmonary hypertension. Am J Cardiol. 1994 Aug 15; 74(4):414-6.
Score: 0.105
-
Vorhies EE, Ivy DD. Drug treatment of pulmonary hypertension in children. Paediatr Drugs. 2014 Feb; 16(1):43-65.
Score: 0.101
-
Siehr SL, Ivy DD, Miller-Reed K, Ogawa M, Rosenthal DN, Feinstein JA. Children with pulmonary arterial hypertension and prostanoid therapy: long-term hemodynamics. J Heart Lung Transplant. 2013 May; 32(5):546-52.
Score: 0.095
-
Krishnan U, Takatsuki S, Ivy DD, Kerstein J, Calderbank M, Coleman E, Rosenzweig EB. Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children. Am J Cardiol. 2012 Dec 01; 110(11):1704-9.
Score: 0.092
-
Abman SH, Ivy DD. Recent progress in understanding pediatric pulmonary hypertension. Curr Opin Pediatr. 2011 Jun; 23(3):298-304.
Score: 0.084
-
Tissot C, Ivy DD, Beghetti M. Medical therapy for pediatric pulmonary arterial hypertension. J Pediatr. 2010 Oct; 157(4):528-32.
Score: 0.079
-
Ivy DD. Prostacyclin in the intensive care setting. Pediatr Crit Care Med. 2010 Mar; 11(2 Suppl):S41-5.
Score: 0.077
-
Ivy DD, Yanagisawa M, Gariepy CE, Gebb SA, Colvin KL, McMurtry IF. Exaggerated hypoxic pulmonary hypertension in endothelin B receptor-deficient rats. Am J Physiol Lung Cell Mol Physiol. 2002 Apr; 282(4):L703-12.
Score: 0.045
-
Douwes JM, Zijlstra WMH, Rosenzweig EB, Ploegstra MJ, Krishnan US, Haarman MG, Roofthooft MTR, Postmus D, Hillege HL, Ivy DD, Berger RMF. Parenteral Prostanoids in Pediatric Pulmonary Arterial Hypertension: Start Early, Dose High, Combine. Ann Am Thorac Soc. 2022 02; 19(2):227-237.
Score: 0.044
-
Parker TA, Ivy DD, Kinsella JP, Torielli F, Ruyle SZ, Thilo EH, Abman SH. Combined therapy with inhaled nitric oxide and intravenous prostacyclin in an infant with alveolar-capillary dysplasia. Am J Respir Crit Care Med. 1997 Feb; 155(2):743-6.
Score: 0.031
-
Maxey DM, Ivy DD, Ogawa MT, Feinstein JA. Food and Drug Administration (FDA) postmarket reported side effects and adverse events associated with pulmonary hypertension therapy in pediatric patients. Pediatr Cardiol. 2013 Oct; 34(7):1628-36.
Score: 0.024
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|